New Hope for Advanced Melanoma Patients..

Among melanoma patients receiving Yervoy (ipilimumab)-Leukine (sargramostim), %69 lived at least another year.
Cancer is a disease that affects the immune system. Its spread through the body increases the risk of death. Preventing this spread is one of the most crucial challenges that the scientific world is trying to address. Dozens of clinical trials and drugs under investigation focus on strengthening the immune system, shrinking tumors, and preventing their spread. The news I will share with you in this article is one of the recent promising positive developments in skin cancer.
Clinical trial results showed that combining Yervoy® (ipilimumab) and Leukine® (sargramostim; GM-CSF), rather than giving Yervoy® alone, may prolong patients' survival in the treatment of advanced (metastatic) melanoma, an aggressive form of skin cancer. These positive findings were presented to the public at the American Society of Clinical Oncology's 2013 annual meeting.
Worldwide, approximately 68,000 of more than a million annual skin cancers are melanoma. Greater spread makes it more dangerous than other skin cancers.
Immunotherapy is a treatment that activates the immune system to attack cancer cells and thereby aims to prevent the disease from spreading. Yervoy, an immune-directed drug used in the treatment of advanced melanoma, targets the CTLA4 molecule on the surface of T cells, the body's defense cells, which inhibits the immune response. Leukine is a growth factor used to increase white blood cell counts following stem cell transplantation or chemotherapy.
By combining these two responses, researchers evaluated the Yervoy-Leukine combination as a treatment. In a clinical trial involving 245 patients with advanced melanoma, some participants were treated with Yervoy alone, while others received the Yervoy-Leukine combination.
In Conclusion;
- Although tumor shrinkage rates were the same in both study groups, %69 of patients treated with the Yervoy-Leukine combination had their lives extended by at least one additional year.
- Fewer serious effects occurred with combination therapy.
The extension of life by at least one year in more than half of patients treated with the Yervoy-Leukine combination is a development too important to ignore. These results also suggest that a safer and more beneficial treatment could be developed for patients with metastatic melanoma. This means an expansion of treatment alternatives, particularly for advanced skin cancer cases.
Although this treatment combination has not yet entered routine use in oncology clinics, I believe it will pass through the approval stages soon and become available to this group of patients.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.